Table 1 Demographics and entry study profiles for non-Parkinsonian subjects and PD patients

From: Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

 

Non-Parkinsonian subjects

PD patients

Demographics a

N

Mean (SD)

N

Mean (SD)

Age (years)

17

65 (7)

20

64 (7)

Time since first symptoms (years)

n/a

n/a

20

7 (3)

Time since diagnosis (years)

n/a

n/a

19

6 (3)

UPDRS III score

n/a

n/a

20

22 (8)

 

N (Percentage)

N (Percentage)

Male sex

9 (53)

16 (80)

Caucasian race

17 (100)

20 (100)

Job with pesticides

1 (5)

2 (10)

Exposure to pesticides

4 (24)

10 (50)

Job with chemical solvents

4 (24)

8 (40)

Job with other chemical fumes

4 (24)

8 (40)

Job with heavy metals

2 (12)

2 (10)

Hematological parameter

Mean (SD)

Mean (SD)

WBC × 103/μL

6.3 (1.4)

6.8 (1.6)

RBC × 106/μL

4.7 (0.4)

4.7 (0.3)

Hemoglobin, g/dL

14.4 (1.1)

14.4 (0.8)

Hematocrit, %

43.2 (6.6)

43.1 (2.2)

Mean corpuscular volume (MCV), fL

91.6 (3.8)

91.3 (4.1)

Mean corpuscular hemoglobin concentration (MCHC), %

33.2 (0.9)

33.4 (0.7)

Red cell distribution width (RDW), %

13.2 (0.7)

13.0 (1.1)

Platelet count × 103/μL

225.6 (37.9)

233.0 (57.6)

Neutrophils, %

61.7 (5.6)

66.0 (6.9)b

Lymphocytes, %

25.4 (6.0)

23.2 (5.7)

Monocytes, %

8.5 (1.9)

7.4 (1.3)

Eosinophils, %

2.9 (1.5)

2.5 (1.4)

Basophils, %

1.0 (0.2)

0.7 (0.4)b

Neutrophil × 103/μL

3.9 (1.0)

4.6 (1.2)

Lymphocytes × 103/μL

1.6 (0.5)

1.6 (0.5)

Monocytes × 103/μL

0.5 (0.1)

0.5 (0.1)

Eosinophils × 103/μL

0.2 (0.1)

0.2 (0.1)

Basophils × 103/μL

0.1 (0.0)

0.0 (0.0)

T cell panel

Mean (SD)

Mean (SD)

CD3+, %

70.5 (7.1)

71.3 (8.5)

CD3+/μL

1162.7 (456.9)

1123.2 (360.6)

CD4+, %

50.9 (7.2)

49.2 (11.0)

CD4+/μL

835.9 (320.9)

769.4 (263.6)

CD8+, %

18.9 (6.4)

21.3 (8.1)

CD8+/μL

316.3 (183.2)

342.6 (195.6)

CD4+/CD8+ Ratio

3.1 (1.0)

2.9 (1.1)

% Teff/CD4+

1.1 (0.4)

1.1 (0.4)

% α4β7 Integrin+/Teff

8.3 (3.5)

14.5 (10.6)b

% Treg/CD4+

5.4 (1.2)

5.4 (1.3)

% FOXP3+/CD4+

8.9 (2.8)

8.7 (2.6)

% CD39+/Treg

55.8 (15.8)

41.6 (23.8)c

% α4β7 Integrin+/Treg

6.2 (2.1)

8.6 (3.0)b

  1. n/a not applicable
  2. a Demographic information obtained from controls and patients at the time of enrollment were used
  3. b P < 0.05
  4. c P ≤ 0.10 by Mann–Whitney U test